Marshall Wace
LAB icon

Marshall Wace’s Standard BioTools LAB Stock Holding History

Marshall Wace’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,145
Closed -$112K – 2809
2024
Q3 		$112K Sell
58,145
-23,472
-29% -$46K ﹤0.01% 2362
2024
Q2 		$144K Hold
81,617
– – ﹤0.01% 2352
2024
Q1 		$221K Buy
81,617
+58,145
+248% +$140K ﹤0.01% 2206
2023
Q4 		$51.9K Hold
23,472
– – ﹤0.01% 2074
2023
Q3 		$68.1K Buy
23,472
+7,300
+45% +$19.1K ﹤0.01% 2067
2023
Q2 		$31.2K Buy
+16,172
New +$31.9K ﹤0.01% 2383
2022
Q3 		– Sell
-93,509
Closed -$149K – 3585
2022
Q2 		$149K Buy
+93,509
New +$231K ﹤0.01% 3220
2021
Q1 		– Sell
-1,278,402
Closed -$7.67M – 2688
2020
Q4 		$7.67M Buy
1,278,402
+438,687
+52% +$2.88M 0.04% 424
2020
Q3 		$6.24M Buy
839,715
+825,080
+5,638% +$5.7M 0.04% 446
2020
Q2 		$59K Buy
+14,635
New +$51K ﹤0.01% 1476
2016
Q2 		– Sell
-17,601
Closed -$142K – 1077
2016
Q1 		$142K Sell
17,601
-79,079
-82% -$570K ﹤0.01% 987
2015
Q4 		$1.04M Buy
+96,680
New +$949K 0.01% 700

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Marshall Wace's LAB Position: Q4 2024 in Review

Marshall Wace sold out of Standard BioTools (LAB) in Q4 2024, closing a stake of 58,145 shares — an estimated $112K sold.

Marshall Wace first reported a position in LAB in Q4 2015 and held it in 12 quarters. The position peaked at $7.67M in Q4 2020. 142 funds tracked by Wall St. Rank hold LAB as of Q4 2024.

  • Marshall Wace reported no remaining Standard BioTools position as of Q4 2024 after selling out during the quarter.
  • Marshall Wace sold 58,145 Standard BioTools shares in Q4 2024, an estimated $112K.
  • Marshall Wace first reported a position in Standard BioTools in Q4 2015 and held it in 12 quarters.
  • Marshall Wace's Standard BioTools position peaked at $7.67M in Q4 2020.
  • 142 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2024.

Based on Marshall Wace's 13F filing for Q4 2024, filed 13 Feb 2025.